Blockchain Registration Transaction Record

Silo Pharma Secures Key Japanese Patent for PTSD Treatment SPC-15

Silo Pharma receives Japan patent allowance for SPC-15, an intranasal PTSD treatment. The development strengthens their IP portfolio in stress-modulating therapeutics.

This patent allowance represents a crucial step in validating Silo Pharma's innovative approach to mental health treatment, particularly for PTSD—a condition affecting millions globally with limited effective pharmaceutical options. The Japanese market approval signals international recognition of their intranasal delivery technology, which could revolutionize how stress-related disorders are treated by potentially offering faster-acting, more targeted therapy with fewer side effects than current oral medications. For patients, this development brings hope for more effective PTSD treatments that address the biological underpinnings of trauma response. For the healthcare industry, it demonstrates the growing legitimacy of novel drug delivery systems and psychedelic-inspired therapeutics in mainstream medicine. The expansion of intellectual property protection in a major pharmaceutical market like Japan also enhances Silo's valuation and partnership potential, potentially accelerating development timelines for much-needed mental health solutions.